Previous Close | 15.84 |
Open | 16.19 |
Bid | 15.53 x 200 |
Ask | 15.76 x 100 |
Day's Range | 15.53 - 16.23 |
52 Week Range | 9.94 - 20.22 |
Volume | |
Avg. Volume | 124,932 |
Market Cap | 776.326M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.04 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 29.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for HLVX
Aditya Kohli, a director at HilleVax Inc (NASDAQ:HLVX), has sold 18,000 shares of the company on March 20, 2024, according to a recent SEC filing.
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 Enrollment for NEST-IN1 study completed in Q2 2023 $303.5 million of cash, cash equivalents and marketable securities as of December 31, 2023 BOSTON, March 20, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the year ended December 31, 2023, highlighted recent
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the Guggenheim 6th Annual Biotechnology Conference in New York, New York on Wednesday, February 7, 2024 at 2:00 p.m. EST. HIL-214, HilleVax’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and th